FY2025 Earnings Forecast for BMY Issued By Cantor Fitzgerald

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Bristol Myers Squibb in a research note issued to investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $6.28 per share for the year, down from their prior forecast of $6.89. Cantor Fitzgerald currently has a “Neutral” rating and a $55.00 price target on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Argus raised shares of Bristol Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 target price for the company. Jefferies Financial Group reduced their target price on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Finally, UBS Group reduced their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $57.69.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $46.91 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65. The firm has a 50-day simple moving average of $47.51 and a 200 day simple moving average of $53.28. The company has a market cap of $95.47 billion, a PE ratio of 17.57, a P/E/G ratio of 2.43 and a beta of 0.36. Bristol Myers Squibb has a fifty-two week low of $39.93 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the prior year, the firm earned ($4.40) EPS. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year.

Institutional Trading of Bristol Myers Squibb

Several hedge funds and other institutional investors have recently modified their holdings of the business. Polar Asset Management Partners Inc. purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $16,651,000. Avaii Wealth Management LLC raised its holdings in shares of Bristol Myers Squibb by 590.9% during the first quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company’s stock worth $4,794,000 after acquiring an additional 67,221 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Bristol Myers Squibb by 1.4% during the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company’s stock worth $3,967,000 after acquiring an additional 869 shares in the last quarter. Shorepoint Capital Partners LLC raised its holdings in shares of Bristol Myers Squibb by 2.2% during the fourth quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company’s stock worth $3,305,000 after acquiring an additional 1,248 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Bristol Myers Squibb by 17.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company’s stock worth $33,582,000 after acquiring an additional 80,087 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm’s stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.